Trinity Biotech announced senior executives will attend ATTD 2026 to advance CGM+ collaborations ahead of a pivotal clinical trial in 2026, following compelling clinical data. The company commenced commercial rollout of its next-generation Premier Hb9210 HbA1c column system in Brazil after regulatory approval and appointed Bruna Gigliotti to lead its Brazilian commercial organization.
Key takeaways
Senior executives attending ATTD 2026 conference in Barcelona to progress CGM+ strategic collaborations and commercialization.
CGM program advancing to pivotal clinical trial in 2026 based on March 10, 2026 clinical performance data.
Commercial rollout commenced in Brazil for next-generation Premier Hb9210 HbA1c column system following local regulatory approval.
Premier Hb9210 platform received IFCC 'Gold' classification for 2026, the only system worldwide.
Bruna Gigliotti joined to lead Trinity Biotech's local Brazilian commercial organization.